



Spring Group Meeting

San Francisco Specials

APRIL 30 - MAY 2, 2026



Prevention, Screening, and
Surveillance Committee

Prevention, Screening, & Surveillance Committee

Leadership

Co-Chairs: Banu Arun, MD
 Jason A. Zell, DO

Time/Location

Thursday, April 30, 2026 4:30 p.m. - 6:30 p.m.
 Room: Bayview Room (Bay Level)

Agenda

1. Welcome and Opening Comments Banu Arun, MD & Jason Zell, DO

2. Frank & Linda Meyskens Lectureship

Integrated Precision Prevention in Early-Onset Colorectal Cancer: From Genetic, Lifestyle, and Environmental Risk Factors to Microbiome Modulation. Ulrike Peters, PhD, MPH, Professor and Associate Director, Public Health Sciences Division, Fred Hutchinson Cancer Institute

3. Closed Studies

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors". Drs. C. Nichols and L. Nappi. Activated: 6/1/20. Closed: 5/20/24.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20. Closed 6/14/24.

4. Concepts in Development

A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial of Finasteride to Prevent Recurrence in Patients with Low-Grade Intermediate-Risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) FIN-BC. Drs. S. Psutka and P. Hensley.

DCISionRT Biomarker for DCIS Concept. Dr. Eileen Connolly.

QuitTech: A Technology-Enhanced Smoking Cessation Program for Cancer Patients and Survivors. Dr. Irene Tami-Maury, DMD, DrPH, MSc

5. Patient Advocate Update

6. Group Discussion

7. Other Group Prevention Studies with SWOG Accrual

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-CC005, "FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)". Dr. L. Kachnic. Activated: 10/6/21.

CTSU/NRG-CC008, "A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]." Activated: 6/23/20

CTSU A212102, "Blinded Reference Set for Multicancer Early Detection Blood Tests." Dr. J. McGuinness. Activated: 8/1/22.

CTSU/EA2185, "Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers"/ Activated: 1/16/20. Temporarily Closed to Accrual as of 3/1/24.

Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S0000/S9217 Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups. Thomas J Hoffmann, Rebecca E Graff, Ravi K Madduri, Alex A Rodriguez, Clinton L Cario, Karen Feng, Yu Jiang, Anqi Wang, Robert J Klein, Brandon L Pierce, Scott Eggener, Lin Tong, William Blot, Jirong Long, Louisa B Goss, Burcu F Darst, Timothy Rebbeck, Joseph Lachance, Caroline Andrews, Akindele O Adebisi, Ben Adusei, Oseremen I Aisuodionoe-Shadrach, Pedro W Fernandez, Mohamed Jalloh, Rohini Janivara, Wenlong C Chen, James E Mensah, Ilir Agalliu, Sonja I Berndt, John P Shelley, Kerry Schaffer, Mitchell J Machiela, Neal D Freedman, Wen-Yi Huang, Shengchao A Li, Phyllis J

Prevention, Screening, & Surveillance Committee

Goodman, Cathee Till, Ian Thompson, Hans Lilja, Dilrini K Ranatunga, Joseph Presti, Stephen K Van Den Eeden, Stephen J Chanock, Jonathan D Mosley, David V Conti, Christopher A Haiman, Amy C Justice, Linda Kachuri, John S Witte. *Nat Genet*. 2025 Feb;57(2):334-344. doi: 10.1038/s41588-024-02068-z. Epub 2025 Feb 10. <https://pubmed.ncbi.nlm.nih.gov/39930085/>

S Dzingle, A Michel, M DeLucie, CW Law, S Pruthi, AC Sandoval Leon, R Shirley, MT Grosse Perdekamp, SV Colonna, SL Krisher, TA King, LD Yee, TJ Ballinger, C Braun-Inglis, DA Mangino, KB Wisinski, CA DeYoung, MRoss, JD Floyd, AKaster, LH VanderWalde, TJ Saphner, C Zarwan, S Lo, C Graham, AK Conlin, K Yost Butler, DM Agnese, C Jernigan, DL Hershman, ML Neuhouser, JA Zell, B Arun, R Kukafka. Submitted 2026.

S9217 Long-term effect estimation when combining clinical trial and observational follow-up datasets. Gang Cheng, Yen-Chi Chen, Joseph M. Unger, Cathee Till, Ying-Qi Zhao. *J Amer Stat Assoc*. 2025 Jul 15:1-10. 10.1080/01621459.2025.2526703.

S9217 Challenges to and considerations of designing cancer prevention trials. Danielle M Enserro, Heather J Gunn, Mohamed I Elsaid, Fenghai Duan, Stephanie L Pugh. *J Natl Cancer Inst Monogr*. 2025 Mar 1;2025(68):49-55. doi: 10.1093/jncimonographs/lgae044. <https://pubmed.ncbi.nlm.nih.gov/39989045/>

S9217 Emerging strategies for drug-based cancer risk reduction. Maria Daca-Álvarez, Angelo Brunori, Alessio Carbone, Chantelle Carbonell, Catherine M Tangen, Joseph M Unger, M Scott Lucia, Martino Oliva, Andrea De Censi, Darren R Brenner, Ian M Thompson Jr, Francesc Balaguer. *Am Soc Clin Oncol Educ Book*. 2025 Jun;45(3):e473708. 10.1200/EDBK-25-473708. <https://pubmed.ncbi.nlm.nih.gov/40435434/>

S9217/Others Dietary Fiber Intake and Risk of Advanced and Aggressive Forms of Prostate Cancer: A Pooled Analysis of 15 Prospective Cohort Studies. Sidahmed E, Freedland SJ, Wang M, Wu K, Albanes D, Barnett M, van den Brandt PA, Cook MB, Giles GG, Giovannucci E, Haiman CA, Larsson SC, Key TJ, Loftfield E, Männistö S, McCullough ML, Milne RL, Neuhouser ML, Platz EA, Perez-Cornago A, Sawada N, Schenk JM, Sinha R, Tsugane S, Visvanathan K, Wang Y, White KK, Willett WC, Wolk A, Ziegler RG, Genkinger JM, Smith-Warner SA. *J Acad Nutr Diet*. 2025 Jan;125(1):11-23.e22. doi: 10.1016/j.jand.2024.04.006. Epub 2024 Apr 16. <https://pubmed.ncbi.nlm.nih.gov/38636793/>

EA1151 Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST). Ping Hu, Jon A Steingrimsson, Elodia Cole, Jean Cormack, Barbara K Dunn, Constantine Gatsonis, Cecilia Lee, Ni Li, Etta D Pisano, Jie He, Barnett S Kramer. *J Natl Cancer Inst Monogr*. 2025 Mar 1;2025(68):42-48. doi: 10.1093/jncimonographs/lgae049. <https://pubmed.ncbi.nlm.nih.gov/39989037/>

Submitted Manuscripts

S1904 Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE. K Crew, GL Anderson, KB Arnold,

Prevention, Screening, and Surveillance Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A211801	A212102	EA1151	EA2185	EA8184	NRGCC005	NRGCC008
Arnot Ogden Medical Center/Falck Cancer Center	-	-	263	-	-	-	-
Audie L Murphy VA Hospital	-	63	-	-	4	2	-
Banner MD Anderson Cancer Center	-	-	1	-	-	-	-
Banner University Medical Center - Tucson	-	-	56	-	-	-	-
Baptist Mem Health Care/Mid So Minority Underserved NCORP	-	-	8	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	3	-	-	6
CWRU Case Comprehensive Cancer Center LAPS	-	2	290	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	2	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	1	-	-
Essentia Health NCI Community Oncology Research Program	-	-	100	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	105	-	-	-	-
Gulf South Minority Underserved NCORP	-	5	-	-	-	-	2
Hawaii Minority Underserved NCORP	-	-	80	-	-	-	-
Henry Ford Hospital	-	4	133	-	-	-	-
Kansas City Veterans Affairs Medical Center	-	14	-	-	-	11	-
Loyola University Medical Center	-	4	-	-	-	-	-
Malcom Randall Veterans Administration Medical Center	-	-	-	-	-	19	-
Massachusetts Veterans Epidemiology Research and Info Center	-	30	-	8	-	64	-
Medical University of South Carolina Minority Underserved NCORP	-	2	4	-	3	-	-
Memorial Hermann Texas Medical Center	-	-	8	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	463	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	1
Oregon Health and Science University	-	-	-	4	3	14	3
Our Lady of the Lake Hospital	-	3	-	-	-	-	-
Regents of the University of Michigan	1	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	6	-	-	-	-	-
Tulane University School of Medicine	-	-	2	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	1	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	124	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	1	-	-	-
University of Arkansas for Medical Sciences	-	-	389	3	-	-	-
University of Colorado Cancer Center LAPS	-	5	2	-	-	16	-
University of Kentucky/Markey Cancer Center	-	-	9	-	-	-	-
University of Texas Health Science Center at San Antonio	-	20	-	-	-	-	1
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	3	-
Upstate Carolina Consortium Comm Oncology Research Program	-	-	619	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	8	-	-	-	-
Western States Cancer Research NCORP	-	1	73	-	-	-	-
Total	1	283	2,615	20	12	129	13

